Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
28
FBIO Quote, Financials, Valuation and Earnings
Last price:
$2.76
Seasonality move
:
14.98%
Day range:
$2.49 - $2.76
52-week range:
$1.33 - $4.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.27x
P/B ratio:
1.49x
Volume:
633.8K
Avg. volume:
358.5K
1-year change:
22.83%
Market cap:
$83.5M
Revenue:
$57.7M
EPS (TTM):
-$0.27
Analysts' Opinion
-
Consensus RatingFortress Biotech, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.75, Fortress Biotech, Inc. has an estimated upside of 299.63% from its current price of $2.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.50 representing 100% downside risk from its current price of $2.69.
Fair Value
-
According to the consensus of 1 analyst, Fortress Biotech, Inc. has 299.63% upside to fair value with a price target of $10.75 per share.
FBIO vs. S&P 500
-
Over the past 5 trading days, Fortress Biotech, Inc. has underperformed the S&P 500 by -0.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fortress Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fortress Biotech, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Fortress Biotech, Inc. reported revenues of $17.6M.
Earnings Growth
-
Fortress Biotech, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Fortress Biotech, Inc. reported earnings per share of $0.11.
Enterprise value:
74.9M
EV / Invested capital:
0.56x
Price / LTM sales:
1.27x
EV / EBIT:
--
EV / Revenue:
1.20x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-2.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$37.5M
Return On Assets:
-34.04%
Net Income Margin (TTM):
-86.41%
Return On Equity:
-223.06%
Return On Invested Capital:
-56.09%
Operating Margin:
-38.63%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $81M | $62.5M | $62.3M | $14.6M | $17.6M | |
| Gross Profit | $49.7M | $36.6M | $37.5M | $9.2M | $10.7M | |
| Operating Income | -$174.2M | -$103.5M | -$92.9M | -$22.1M | -$6.8M | |
| EBITDA | -$165.1M | -$96.1M | -$86.4M | -$20.7M | -$5.2M | |
| Diluted EPS | -$24.88 | -$3.28 | -$0.27 | -$0.76 | $0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $301.2M | $258M | $97.8M | $86.3M | $118.5M | |
| Total Assets | $407.8M | $323.6M | $150.5M | $127.1M | $181.4M | |
| Current Liabilities | $103.2M | $106.3M | $97.4M | $70.3M | $54.1M | |
| Total Liabilities | $195.4M | $222.2M | $163.8M | $139.8M | $116.2M | |
| Total Equity | $212.5M | $101.4M | -$13.2M | -$12.7M | $65.2M | |
| Total Debt | $90.1M | $123.1M | $67.7M | $69M | $66.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$141.1M | -$153.2M | -$15.1M | -$71.1M | -$6.1M | |
| Cash From Investing | -$2.4M | -$63K | -$4.9M | -- | $2.9M | |
| Cash From Financing | $7.7M | $139.5M | $46.5M | $53.7M | $15.1M | |
| Free Cash Flow | -$149.6M | -$153.3M | -$30.1M | -$71.1M | -$6.1M | |
FBIO
Sector
Market Cap
$83.5M
$28.4M
Price % of 52-Week High
64.05%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-83.88%
-1.32%
1-Year Price Total Return
22.83%
-22.19%
Beta (5-Year)
1.490
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.67
200-day SMA
Buy
Level
$2.18
Bollinger Bands (100)
Buy
Level
2.04 - 3.24
Chaikin Money Flow
Buy
Level
2.7M
20-day SMA
Buy
Level
$2.62
Relative Strength Index (RSI14)
Buy
Level
51.25
ADX Line
Sell
Level
9.16
Williams %R
Neutral
Level
-36.2637
50-day SMA
Sell
Level
$2.77
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
9.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.9468)
Sell
CA Score
(Annual)
Level (-5.1662)
Sell
Beneish M-Score
(Annual)
Level (-1.7153)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (7.8079)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Stock Forecast FAQ
In the current month, FBIO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FBIO average analyst price target in the past 3 months is $10.75.
-
Where Will Fortress Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fortress Biotech, Inc. share price will rise to $10.75 per share over the next 12 months.
-
What Do Analysts Say About Fortress Biotech, Inc.?
Analysts are divided on their view about Fortress Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fortress Biotech, Inc. is a Sell and believe this share price will drop from its current level to $4.50.
-
What Is Fortress Biotech, Inc.'s Price Target?
The price target for Fortress Biotech, Inc. over the next 1-year time period is forecast to be $10.75 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is FBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fortress Biotech, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of FBIO?
You can purchase shares of Fortress Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fortress Biotech, Inc. shares.
-
What Is The Fortress Biotech, Inc. Share Price Today?
Fortress Biotech, Inc. was last trading at $2.76 per share. This represents the most recent stock quote for Fortress Biotech, Inc.. Yesterday, Fortress Biotech, Inc. closed at $2.69 per share.
-
How To Buy Fortress Biotech, Inc. Stock Online?
In order to purchase Fortress Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FBIO
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
1.49x
1.84x
Price / LTM sales
1.27x
1.60x
Growth Metrics
FBIO
Sector
Revenue growth
20.52%
4.85%
Earnings growth
114.54%
11.15%
Revenue (5-year growth)
9.51%
6.45%
Earnings forecast
-$0.31
-$0.20
Profitability
FBIO
Sector
Profitability FY 2024
$32.3M
$3.6M
Return on invested capital
-56.09%
-30.98%
Return on assets
-34.04%
-27.62%
Return on equity
-223.06%
-36.69%
Earnings Date
Last Earnings Date
Aug
13
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
FBIO
Sector
Total cash
$86.2M
$27.2M
Short term investments
--
$25.7M
Total assets
$144.2M
$79.9M
Long term debt
$66.2M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
